A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms PC03
- 07 Jun 2017 Biomarkers information updated
- 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 08 May 2013 Planned End Date changed from 1 Feb 2020 to 1 Feb 2022 as reported by ClinicalTrials.gov.